Comparison of efficacy and tolerability of palonosetron administered once, twice, and three times before haemotopoietic stem cell transplantation in multiple myeloma patients receiving melphalan and dexamethasone.

Trial Profile

Comparison of efficacy and tolerability of palonosetron administered once, twice, and three times before haemotopoietic stem cell transplantation in multiple myeloma patients receiving melphalan and dexamethasone.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Feb 2011

At a glance

  • Drugs Palonosetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top